Jump to Your Goal
đ©č Injury, Tendons & Soft Tissue Repair
BPC-157
The most talked-about tissue-repair peptide, period. Derived from a protein found in gastric juice. Preclinical research shows it accelerates healing of tendons, ligaments, muscle, and gut tissue, likely through angiogenesis (new blood vessel formation) and growth factor modulation. The injury community's default pick for tendinopathy.
Evidence: Extensive animal data, only 3 small published human studies. Not FDA-approved. On FDA Category 2 list (Sept 2023).
TB-500 (Thymosin Beta-4 fragment)
Commonly stacked with BPC-157 because they hit repair through different mechanisms. TB-500 is studied for actin regulation, cell migration to injury sites, and anti-inflammatory effects. Often chosen for broader systemic injuries or where multiple tissues are involved.
Evidence: Preclinical + limited human trials (mostly cardiac-focused). Not FDA-approved.
GHK-Cu
Often added when skin/wound healing is part of the picture. Copper peptide with documented effects on collagen synthesis and tissue remodeling. Less about tendon and more about skin, scars, and surface tissue.
Evidence: Decades of research in dermatology and wound care.
đ„ The Popular Stack: WOLVERINE
BPC-157 + TB-500. The most common injury-repair combination in the peptide community. Users report complementary effects (BPC-157 for local tissue, TB-500 for systemic recovery). Read the full breakdown â
Honest note: No published studies have evaluated this specific combination as a blend. The logic is based on each peptide's individual mechanism.
đ The cellular recovery angle: NAD+ and SS-31
The peptides above target tissue-level repair. There's a parallel recovery story at the cellular level, mitochondrial damage and the slow recovery that comes with age or chronic stress. NAD+ supports mitochondrial ATP production and sirtuin activity. SS-31 binds cardiolipin in the mitochondrial membrane to reduce oxidative damage. Not first-line for an acute tendon injury, but worth knowing about for chronic-fatigue-style recovery or when age-related slowdown is the issue.
Honest note: Most evidence is preclinical or longevity-focused. SS-31 has progressed through Phase 3 trials for primary mitochondrial myopathy under the name Elamipretide, but is not yet FDA-approved. NAD+ is a coenzyme rather than a peptide.
âïž Fat Loss & Weight Management
Tirzepatide (Mounjaro / Zepbound)
Currently the most effective FDA-approved weight-loss medication available. Dual GIP/GLP-1 agonist. Average weight loss in clinical trials: ~22% of body weight over 72 weeks at the highest dose. This is the category leader for serious, sustainable fat loss.
Evidence: FDA-approved 2022 (diabetes), 2023 (weight). SURMOUNT trials, robust Phase 3 data.
Semaglutide (Ozempic / Wegovy)
The GLP-1 that kicked off the whole wave. Average weight loss: ~15-17% body weight. More clinical history, better-established safety profile, usually more affordable. A solid choice if tirzepatide isn't accessible.
Evidence: FDA-approved. STEP trials, extensive post-market data.
Retatrutide (investigational)
Triple agonist (GLP-1 + GIP + glucagon). Phase 2 trials showed up to ~24% body weight loss. Not yet approved, expected 2027-2028. This is what's coming, not what you can get now.
Evidence: Phase 3 TRIUMPH trials ongoing. Not FDA-approved.
Tesamorelin (for visceral fat specifically)
FDA-approved specifically for HIV-associated lipodystrophy, but studied off-label for visceral (abdominal) fat. Not for general weight loss, it's narrow: it targets fat around organs rather than overall body fat.
Evidence: FDA-approved for narrow indication. Off-label use for visceral fat has published data.
đ What about AOD-9604?
AOD-9604 is often marketed as a "fat loss peptide" based on a modified fragment of growth hormone. Honest take: human trials have largely failed to show meaningful weight loss. It's not in the same league as GLP-1s. Read the honest breakdown â
đ What's emerging in the GLP-1 pipeline
The GLP-1 category is moving fast. Past Tirzepatide, Semaglutide, and Retatrutide, several next-generation drugs are at various stages of development. Mazdutide is a GLP-1/glucagon dual agonist approved in China in 2025. CagriSema is a Phase 3 combination of Semaglutide and the amylin analog Cagrilintide. Survodutide is another Phase 3 dual agonist (GLP-1/glucagon) being studied in obesity and MASH (liver disease).
Honest note: None of these are FDA-approved or available in the U.S. as of May 2026 (except through ongoing clinical trials). They're worth knowing about for context, not as something you can choose between today.
đȘ Muscle Growth & Athletic Performance
CJC-1295 + Ipamorelin
The classic GH-release stack. CJC-1295 increases baseline GH levels; Ipamorelin produces a clean GH pulse without significantly spiking cortisol or prolactin (unlike older GHRPs). Studied for recovery, body composition, and sleep quality indirectly.
Evidence: CJC-1295 has published PK data; Ipamorelin has limited human trials. Neither FDA-approved.
See also: solo CJC-1295 and solo Ipamorelin profiles for the individual mechanisms.
Tesamorelin
A GHRH analog with more robust clinical data than most growth-hormone peptides. FDA-approved for lipodystrophy, but the GH-elevating effect is what draws athletic interest.
Evidence: FDA-approved. Strong published PK/PD data.
MOTS-c
Mitochondrial-derived peptide studied for metabolic flexibility, insulin sensitivity, and exercise performance. Animal data suggests it may improve running capacity and glucose handling.
Evidence: Preclinical data is interesting; human data is limited.
Sermorelin
The original GHRH analog and the parent compound that Tesamorelin descended from. Was FDA-approved as Geref® from 1997 to 2008 (withdrawn for commercial reasons, not safety), now compounded for off-label adult use. Shorter half-life produces a more physiologically natural pulsatile pattern, which is the main reason some research-community protocols still prefer it over Tesamorelin or CJC-1295.
Evidence: Strong human safety data from the 10+ years of FDA-approved clinical use. Adult body composition data is less rigorous.
đ The direct anabolic peptides: IGF-1 LR3, MGF, PEG-MGF
Past the GH-secretagogue stacks above, there's a separate family of peptides studied for direct hypertrophy and tissue growth. IGF-1 LR3 is a long-acting IGF-1 analog. MGF and PEG-MGF are mechano growth factor variants studied post-exercise for localized muscle growth.
Honest note: Human data on all three is limited. Cancer-biology concerns from sustained tissue exposure to elevated IGF-1 are real and unresolved. These are higher-risk, lower-evidence options than the GH secretagogues, and not what most people should reach for first.
đŽ Sleep Quality & Deep Sleep
CJC-1295 + Ipamorelin (nighttime dose)
The #1 reason people take this stack, dosed before bed, it tends to deepen slow-wave sleep. GH release peaks during deep sleep, and this stack amplifies that pulse. Users often report more vivid dreams and feeling more rested even at the same sleep duration.
Evidence: GH-sleep link is well established. Specific outcome data on the stack for sleep is mostly anecdotal.
See also: solo CJC-1295 and solo Ipamorelin profiles for the individual mechanisms.
DSIP (Delta Sleep-Inducing Peptide)
The most literally-named sleep peptide, discovered in the 1970s after being isolated from the cerebral venous blood of sleeping rabbits. Studied for its ability to promote slow-wave (delta) sleep, normalize disrupted sleep architecture, and reduce sleep-onset latency. Also investigated for stress resilience, chronic pain disruption of sleep, and opioid/alcohol withdrawal sleep issues.
Evidence: Several small clinical trials from the 1980s-90s (mostly European); modern replication is limited. Not FDA-approved. Short half-life (~7 minutes) makes consistent effects tricky.
Epitalon
A tetrapeptide studied in Russia for melatonin regulation and pineal gland function. Typically run in short cycles (10-20 days). Reported to normalize circadian rhythm in older adults.
Evidence: Russian clinical literature; limited Western peer-reviewed data.
Selank
If anxiety is disrupting your sleep, Selank is studied as an anxiolytic without sedation. Not a sleep peptide per se, but can help the falling-asleep problem if your mind is racing.
Evidence: Russian clinical data. No Western FDA approval.
đ DSIP vs. CJC/Ipa for sleep
Different mechanisms, different feels. CJC-1295 + Ipamorelin deepens sleep via the GH pulse, users often report vivid dreams and better morning recovery. DSIP targets sleep architecture and delta-wave activity more directly, and is often chosen for fragmented sleep or when the issue is quality, not quantity. Some users cycle or stack them.
âš Skin Quality, Hair & Aesthetic
GHK-Cu
The gold standard copper peptide. Decades of research. Stimulates collagen, elastin, glycosaminoglycans, and has documented wound-healing effects. Widely used in cosmetic dermatology, both topical and injectable research.
Evidence: Strong, extensive dermatology literature.
BPC-157
Often added for general tissue repair and its reported effects on scarring and wound healing.
Evidence: Preclinical data for skin; mostly animal models.
đ„ The Popular Stack: GLOW
GHK-Cu + BPC-157 + TB-500. The skin/regeneration blend. GHK-Cu drives collagen and skin-level repair; BPC-157 and TB-500 add systemic tissue support. Read the full breakdown â
đ„ The Stronger Stack: KLOW
GLOW + KPV. Adds KPV's anti-inflammatory action via NF-ÎșB inhibition. Chosen when inflammation is part of the skin picture (rosacea-type presentations, irritation-prone skin). Read the full breakdown â
đ§ Focus, Memory & Cognitive Performance
Semax
Russian-developed heptapeptide. Studied for BDNF upregulation, neuroprotection, and cognitive enhancement. Commonly used intranasally. Reports of improved focus and mental energy without stimulant-like jitters.
Evidence: Extensive Russian clinical literature; approved there for stroke recovery. Not FDA-approved.
Selank
Often paired with or alternated against Semax. More anxiolytic-leaning; useful when mental performance is hampered by anxiety or stress.
Evidence: Russian clinical data.
Dihexa
Investigational angiotensin IV analog. Preclinical data is striking on synapse formation and cognitive tasks. But, almost no human data. High-interest, high-uncertainty territory.
Evidence: Preclinical only. No human trials published.
đ„ The Russian-tradition stack: Semax + Selank
The most-discussed pairing in this category. Semax + Selank combines cognitive lift (Semax, BDNF/NGF) with anxiolytic effect (Selank, GABA/serotonin) in one intranasal stack. Both peptides come from the same Khavinson research lineage and target distinct mechanisms, so the theoretical case for combining them is reasonable on paper. Full blend explainer with the dose calculator →
Honest note: Zero published human trials of the specific combination — the stack is community wisdom built on the individual peptides' Russian clinical histories.
đ The brain energy angle: NAD+
Semax, Selank, and Dihexa target neurotransmitter and growth-factor pathways. There's a parallel cognitive conversation focused on cellular energy metabolism. The brain consumes about 20% of the body's energy at rest, making it especially sensitive to declining NAD+ levels (which fall measurably with age). Restoring NAD+ is studied for mid-day cognitive fatigue, age-related mental sharpness decline, and supporting recovery after intense mental work. Common forms: subcutaneous NAD+, IV NAD+ drips, and oral precursors NMN and NR.
Honest note: Most NAD+ cognitive research is preclinical or small pilot studies. Subjective reports are common; rigorous controlled trials in healthy adults are limited. NAD+ is not FDA-approved for cognitive enhancement. It's a coenzyme rather than a peptide.
đ Don't skip the basics: Vitamin B12
Before reaching for nootropic peptides for fatigue or "brain fog," check whether you have a real B12 deficiency. It's surprisingly common (especially in older adults, vegans/vegetarians, people on metformin or PPIs, and anyone with GI absorption issues) and can produce exactly the cognitive and energy symptoms most peptide protocols target. Injectable B12 reliably corrects diagnosed deficiency — FDA-approved for that indication, with decades of evidence. The blood test is cheap and widely available.
Honest note: If your B12 level is normal, B12 shots in non-deficient people don't reliably do anything; the body excretes the excess in urine. Test first.
đż Anxiety, Stress & Mood
Selank
The #1 peptide choice for anxiety. Non-sedating anxiolytic. Studied for generalized anxiety, stress, and cognitive function under pressure. Acts on GABA and serotonin systems indirectly.
Evidence: Russian clinical trials. Approved in Russia; not FDA-approved.
Semax
Not primarily an anxiolytic, but the mood-stabilizing and neuroprotective effects help some users feel more level.
Evidence: Russian clinical data.
đ„ The combined approach: Semax + Selank blend
If you're looking for both anxiolytic effect and cognitive support in one stack, the Semax + Selank blend combines them in a single intranasal protocol. Selank handles the anxiety; Semax adds focus and mental clarity. Same Russian Khavinson research lineage, complementary mechanisms. Full blend explainer with the dose calculator →
đ« Gut Health, IBD & GI Repair
BPC-157 (oral)
BPC-157 was literally discovered in gastric juice, this is its home turf. Preclinical data for ulcer healing, IBD, and intestinal repair is the most robust part of its research base. Often taken orally specifically for gut issues.
Evidence: Extensive preclinical data in GI models. Limited human trials.
KPV
Anti-inflammatory tripeptide (fragment of α-MSH). Studied specifically for colitis and IBD through NF-ÎșB inhibition. Often oral/rectal administration for direct gut targeting.
Evidence: Preclinical IBD models show strong anti-inflammatory effects.
đ„ Common Gut Stack
BPC-157 + KPV. Pairs gut-tissue repair with anti-inflammatory action. Common in communities dealing with chronic GI conditions.
đĄïž Immune Support & Chronic Infection Resilience
Thymosin Alpha-1
The most clinically validated immune-modulating peptide on the site. Approved in 35+ countries (not the US) for immune conditions. Used adjunctively in hepatitis B/C, severe infections, and immune deficiency.
Evidence: Strong international clinical data. Not FDA-approved in the US.
KPV
Anti-inflammatory modulator. Often chosen when the goal is reducing inflammation rather than boosting immune aggression.
Evidence: Preclinical + limited human data.
âł Longevity, Anti-Aging & Cellular Health
Epitalon
The headline longevity peptide. Studied for telomerase activation and pineal gland function. Russian clinical data in older adults shows normalization of melatonin rhythm and various biomarkers. Typically run 10-20 days 1-2x per year.
Evidence: Russian clinical literature; limited Western replication.
SS-31 (Elamipretide)
Mitochondrial-targeted peptide. Studied specifically for mitochondrial dysfunction, a root cause in aging. Clinical trials in primary mitochondrial myopathy. This is real investigational pharma, not a gray-market peptide.
Evidence: Phase 3 trials completed; pharma development ongoing.
MOTS-c
Another mitochondrial-derived peptide. Studied for metabolic health, insulin sensitivity, and exercise capacity, all downstream of mitochondrial health.
Evidence: Preclinical + early human data.
NAD+
Not strictly a peptide, but part of the same conversation. NAD+ declines with age, and supplementation is studied for cellular energetics and DNA repair pathways.
Evidence: Growing but mixed data in humans.
â€ïžâđ„ Libido & Sexual Function
PT-141 (Bremelanotide / Vyleesi)
FDA-approved (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Works centrally (on brain melanocortin receptors), not on blood flow like PDE5 inhibitors. Studied off-label in men.
Evidence: FDA-approved. Phase 3 clinical data.
Kisspeptin
Works upstream of the hormonal cascade, kisspeptin is the master regulator of GnRH release, which drives LH/FSH and ultimately testosterone and estrogen. Studied in human trials at Imperial College London for low libido, HSDD, and hypothalamic reproductive dysfunction in both men and women. Unlike PT-141 (which hits central arousal pathways), kisspeptin works by restoring the endocrine signal itself. Often the pick when the root issue looks hormonal rather than purely psychological.
Evidence: Multiple published human trials (Imperial College group). Not FDA-approved. Active clinical development.
đ PT-141 vs. Kisspeptin, which one?
PT-141 is acute and central, take it before the moment, feel a shift in arousal and desire within hours. Kisspeptin is systemic and endocrine, it's about fixing the underlying hormonal signaling over time. Different tools for different problems. Some research groups are exploring whether they can be complementary.
𩮠Joint & Connective Tissue Issues
BPC-157
Cross-over pick from the injury category. Commonly used in joint contexts for its effects on connective tissue health.
Evidence: Preclinical. Limited human data.
Pentosan Polysulfate (PPS / Elmiron)
FDA-approved for interstitial cystitis but used widely in Australia for osteoarthritis (where it's approved under the brand Cartrophen). Studied for cartilage preservation.
Evidence: FDA-approved for IC. OA approval exists in some countries. Carries a maculopathy warning.
Still Not Sure?
Browse every peptide we cover with full research detail, FDA status, dosing ranges, and side effects.